BIOMAT Database Logo BIOMAT Database Logo

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. 1996

J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.

A series of substituted monocyclic and bicyclic azepinones were incorporated as dipeptide surrogates in mercaptoacetyl dipeptides with the desire to generate a single compound which would potently inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Many of these compounds displayed excellent potency against both enzymes. Two of the most potent compounds, monocyclic azepinone 2n and bicyclic azepinone 3q, demonstrated a high level of activity versus ACE and NEP both in vitro and in vivo.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
January 2001, Heart disease (Hagerstown, Md.),
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Angiotensin converting enzyme inhibitors: N-substituted monocyclic and bicyclic amino acid derivatives.
September 1983, Journal of medicinal chemistry,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
December 1995, Journal of medicinal chemistry,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors.
November 1996, Journal of cardiovascular pharmacology,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.
November 1993, Journal of medicinal chemistry,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
August 1996, Journal of medicinal chemistry,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
January 1998, Journal of cardiovascular pharmacology,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
April 1999, Clinical pharmacology and therapeutics,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
February 1996, European journal of pharmacology,
J A Robl, and M P Cimarusti, and L M Simpkins, and B Brown, and D E Ryono, and J E Bird, and M M Asaad, and T R Schaeffer, and N C Trippodo
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
July 1995, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!